{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:11Z","timestamp":1793382971649,"version":"4.5.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>BIC\/FTC\/TAF showed efficacy and tolerability in randomized trials as a switch strategy in virologically-suppressed people living with HIV. We evaluated its effectiveness in a real-life setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective monocentric cohort including 431 virologically-suppressed (HIV-RNA &lt;50 copies\/ml) people switching to BIC\/FTC\/TAF in the period 2018\u20132022 was evaluated. Probabilities of virological failure (VF, i.e.2 consecutive HIV-RNA \u226550 copies\/ml or a single HIV-RNA \u2265200 copies\/ml) and of treatment discontinuation (TD) were estimated by Kaplan\u2013Meier, and predictors of both outcomes were identified through multivariable Cox regression. Analysis-of-variance for repeated measures was used to examine changes in CD4 count and CD4-to-CD8 ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 16 VF occurred during 22 months of median follow-up time. Estimated probabilities of VF at 1, 2 and 3 years were 2.0% (95% CI 1.04.2%), 2.9% (95% CI 1.5%\u20135.6%) and 5.5% (95% CI 3.2%\u20139.2%), respectively. Caucasian ethnicity and a history of previous VF independently predicted VF. TD occurred in 42 cases, predominantly for simplification. One discontinuation due to VF was reported. No predictors of discontinuation were identified. An increase in CD4-to-CD8 ratio over 3 years was evidenced (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). Total cholesterol decreased over 3 years (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). Triglycerides did not significantly change (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.465).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BIC\/FTC\/TAF demonstrated high effectiveness, tolerability and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535241306467","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:15:55Z","timestamp":1734592555000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4544-3373","authenticated-orcid":false,"given":"RA","family":"Passerotto","sequence":"first","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lamanna","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PF","family":"Salvo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Iannone","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RJ","family":"Steiner","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Carbone","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Farinacci","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"D'Angelillo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Baldin","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-883X","authenticated-orcid":false,"given":"A","family":"Ciccullo","sequence":"additional","affiliation":[{"name":"Ospedale San Salvatore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Torti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore"},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Borghetti","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Pisana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S23523018(20)30099-0"},{"key":"e_1_3_4_4_2","volume-title":"Effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (BTC\/FTC\/TAF) in ART-naive patients: real-world data from the ICONA cohort","author":"Tavelli A","year":"2022","unstructured":"Tavelli A, Marchetti G, Vergori A, et al. Effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (BTC\/FTC\/TAF) in ART-naive patients: real-world data from the ICONA cohort. HIV Glasgow, 2022. poster P060."},{"key":"e_1_3_4_5_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. (2019, accessed 10 July 2024)","author":"Department of Health and Human Services.","year":"2019","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. (2019, accessed 10 July 2024). DHHS, 2019."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz347"},{"key":"e_1_3_4_9_2","unstructured":"Trottier B Antinori A De Wet J et al. Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age race sex adherence and late presentation in a multi-country cohort study. HIV Glasgow 2022 poster P067."},{"key":"e_1_3_4_10_2","article-title":"Effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort","author":"D\u2019Arminio Monforte A","year":"2022","unstructured":"D\u2019Arminio Monforte A, Tavelli A, Cingolani A, et al. Effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort. HIV Glasgow 2022; (poster P098).","journal-title":"HIV Glasgow"},{"key":"e_1_3_4_11_2","first-page":"232595822211402","article-title":"Real world data on forgiveness to uncomplete adherence to bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"21","author":"Maggiolo F","year":"2022","unstructured":"Maggiolo F, Valenti D, Teocchi R, et al. Real world data on forgiveness to uncomplete adherence to bictegravir\/emtricitabine\/tenofovir alafenamide. J Int Assoc Phys AIDS Care 2022; 21: 23259582221140208.","journal-title":"J Int Assoc Phys AIDS Care"},{"key":"e_1_3_4_12_2","first-page":"232595822211018","article-title":"Adherence to and forgiveness of 3TC\/DTG in a real-world cohort","volume":"21","author":"Maggiolo F","year":"2022","unstructured":"Maggiolo F, Valenti D, Teocchi R, et al. Adherence to and forgiveness of 3TC\/DTG in a real-world cohort. J Int Assoc Phys AIDS Care 2022; 21: 23259582221101815.","journal-title":"J Int Assoc Phys AIDS Care"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002562"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010076"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15061222"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03477-7"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101412"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535241306467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535241306467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535241306467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:15Z","timestamp":1777380795000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535241306467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/13596535241306467"],"URL":"https:\/\/doi.org\/10.1177\/13596535241306467","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"article-number":"13596535241306467"}}